Request a Representative
search

Common Questions

What is the safety profile of ACTIMMUNE®?

What is the efficacy of ACTIMMUNE®?

What is the preferred test for CGD?

Have questions? Call for answers.

Contact us at

1-877-305-7704

9:00 AM to 7:00 PM ET

Download these resources to learn more about CGD and help your patients get access to treatment.

Patient Enrollment Forms
CGD Resources
Payor Access

Patient Enrollment Forms

Patient Enrollment Form

Download the form, complete it with your patient, including HCP signature, and submit by fax or email.

Download PDF

Icon of ACTIMMUNE® (Interferon gamma-1b) Patient Enrollment Form

ACTIMMUNE®Annotated Patient Enrollment Form

Initiate the process to enroll patients prescribed ACTIMMUNE® in Horizon By Your Side.

Download PDF

Icon of ACTIMMUNE® (Interferon gamma-1b) Annotated Patient Enrollment form

CGD Resources

X-Linked Chronic Granulomatous Disease (CGD)

Review the case histories of 2 male patients with X-linked CGD and how they found success with adherence.

Download PDF

Icon of X-linked chronic granulomatous disease (CGD) case study

Autosomal Recessive Chronic Granulomatous Disease (CGD)

Review the case histories of 2 female patients with autosomal recessive CGD and their journeys to treatment with ACTIMMUNE®.

Download PDF

Icon of autosomal recessive chronic granulomatous disease (CGD) case study

Payor Access

ACTIMMUNE® Letter of Medical Necessity (CGD)

A customizable letter template for HCPs who are submitting a Prior Authorization (PA) for specific ACTIMMUNE® CGD patient cases seeking payor access.

Download

Icon of ACTIMMUNE® (Interferon gamma-1b) Letter of Medical Necessity (CGD)

ACTIMMUNE® Letter of Medical Necessity (SMO)

A customizable letter template for HCPs who are submitting a Prior Authorization (PA) for specific ACTIMMUNE® SMO patient cases seeking payor access.

Download

Icon of ACTIMMUNE® (Interferon gamma-1b) Letter of Medical Necessity (SMO)

ACTIMMUNE® Prior Authorization Checklist

Provides a checklist of the common criteria that may be requested for ACTIMMUNE®.

Download PDF

Icon of ACTIMMUNE® (Interferon gamma-1b) Prior Authorization Checklist

ACTIMMUNE® Payor Appeal Letter Checklist and Tips

Provides a checklist and tips that may be useful when creating an appeal letter after a prior authorization request is denied by your patient’s health plan.

Download

Icon of ACTIMMUNE® (Interferon gamma-1b) Payor Appeal Letter Checklist and Tips

ACTIMMUNE® Payor Appeal Letter Template

A customizable letter template for HCPs who are submitting an appeal for specific ACTIMMUNE® patient cases that were denied Prior Authorization (PA).

Download

Icon of ACTIMMUNE® (Interferon gamma-1b) Payor Appeal Letter Template

ACTIMMUNE® Payor Access Roadmap

A resource to help educate healthcare providers about patient access and coverage.

Download

Icon of ACTIMMUNE® (Interferon gamma-1b) Access Journey Roadmap

Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE
  • Pregnancy, Lactation, and Fertility:
    • ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
    • Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
    • Long-term effects of ACTIMMUNE on fertility are not known

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness

Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE
  • Pregnancy, Lactation, and Fertility:
    • ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
    • Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
    • Long-term effects of ACTIMMUNE on fertility are not known

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness
Back to top